Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Patient involvement in medical publications
Michael Pellegrino, SVP of Global Medical Communications, outlines research on patient involvement in the journal review process.
-
News travels fast - The evolution and revolution within medical communications
Michael Pellegrino, SVP of Global Medical Communications weighs in on how industry has increasingly recognised the benefits of different communications for specific purposes and audiences.
-
Testing transmission in the community
ICON’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, talks to Politico on clinical trials to test COVID-19 transmission in the community
-
ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial
An article explaining how ICON was involved from the very first steps of the trial supporting Pfizer‘s and BioNTech’s implementation of a strategic plan and framework for the monitoring of the trial.
-
Irish pharma group ICON carried out trial of Pfizer-BioNTech vaccine
The Irish Times discusses how ICON carried out the Pfizer-BioNTech vaccine trials.
-
BARDA wants you
An article from Pharma Manufacturing which explains why BARDA is looking to recruit more partners in Pharma, featuring commentary from ICON's Dr. James Cummings.
-
Pharma’s digital transformation – How to best incorporate wearables amid an evolving landscape
A thought leadership piece which examines how disruptions from COVID-19 have forced sponsors, clinicians and regulators to embrace digital's full potential to keep clinical trials moving forward.
-
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
Decentralised & hybrid trials: The future of clinical trials post pandemic
An interview with EB McLindon, Senior VP, Patient, Site & Decentralised Solutions, on why the future of drug development involves decentralising parts of the clinical trial process.
-
Moving from on-site" to agile: The changing dynamic in study management"
Pharmafocus (pages 16-17) features a thought leadership piece by Rose Kidd which examines the benefits of agile clinical monitoring in study management.
